| ²é¿´: 251 | »Ø¸´: 0 | |||
´å¿ÚÒ»¶×ľ³æ (ÖøÃûдÊÖ)
ÎÞ
|
[½»Á÷]
¡¾ÇóÖú¡¿ÇóÖú¹þ£¬°ï°ï棬ÇóÈ«ÎÄ
|
|
1¡¢Diabetes Care. 2009 Jul;32(7):1237-43. Epub 2009 Apr 14. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. 2¡¢Horm Metab Res. 2009 Dec;41(12):905-9. Epub 2009 Aug 24. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. 3¡¢Horm Metab Res. 2009 May;41(5):368-73. Epub 2009 Feb 16. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy 4¡¢Horm Metab Res. 2008 Dec;40(12):892-5. Epub 2008 Aug 22. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. 5¡¢Horm Metab Res. 2007 Mar;39(3):218-23. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. 6¡¢Horm Metab Res. 2006 Jun;38(6):423-8. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. 7¡¢Diabetes Care. 2005 Aug;28(8):1936-40. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. 8¡¢Horm Metab Res. 2008 Jun;40(6):427-30. Epub 2008 Mar 11.£¨ÒѾÕÒµ½È«ÎÄ£© Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. |
» ²ÂÄãϲ»¶
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ16È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´














»Ø¸´´ËÂ¥